Chester County News and Community Website
WILMINGTON, DE — AstraZeneca secured U.S. approval for its IMFINZI (durvalumab) regimen in combination with FLOT chemotherapy for early-stage and locally advanced gastric and gastroesophageal junction cancers, marking the first …
AstraZeneca Wins Landmark Approval for IMFINZI Regimen in Early Gastric Cancer Read More
WILMINGTON, DE — ChristianaCare has opened a first-of-its-kind organoid core inside a community cancer program, creating a new laboratory capable of growing patient-derived “mini tumors” to guide more precise and …
New ‘Tumor-on-a-Chip’ Lab Promises Breakthroughs for Delaware Cancer Patients Read More
PHILADELPHIA, PA — Medicus Pharma Ltd. (NASDAQ: MDCX) has submitted a federal priority-review request for its investigational SkinJect microneedle patch, a dissolvable doxorubicin-based therapy designed to non-invasively treat basal cell …
Skin Cancer Breakthrough? Pharma Firm Seeks Fast-Track FDA Voucher for Novel Patch Read More
KING OF PRUSSIA, PA — SEED Therapeutics announced that China’s National Medical Products Administration has cleared the Investigational New Drug application for ST-01156, enabling Chinese sites to participate in the …
China Clears IND for SEED Therapeutics’ First-in-Class Cancer Drug in Global Trial Push Read More
WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) unveiled compelling new data from its Phase 2 study of VP-315, a first-in-class oncolytic peptide immunotherapy, showing strong local immune activation …
New Cancer Data Hints at a Surgery-Free Future — Verrica’s VP-315 Shows Big Promise Read More
PHOENIXVILLE, PA — Facet Life Sciences has entered a strategic partnership with XCancer®, a global leader in theranostic clinical research, to accelerate the development and regulatory approval of next-generation radiopharmaceutical …
Facet Life Sciences and XCancer Join Forces to Speed Cancer Therapy Approvals Read More
PHILADELPHIA, PA — Tolerance Bio announced the publication of new research showing that lab-grown human thymic organoids can restore immune function and suppress tumor growth in melanoma, marking a potential …
Tolerance Bio Study Demonstrates Breakthrough in Regenerating Immune Function to Fight Cancer Read More
WILMINGTON, DE & CINCINNATI, OH — Incyte (NASDAQ: INCY) and Enable Injections have formed a strategic partnership to co-develop and commercialize targeted cancer therapies using Enable’s enFuse® On-Body Delivery System, …
Incyte and Enable Injections Join Forces to Advance At-Home Cancer Treatments Read More WILMINGTON, DE — The U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for AstraZeneca’s supplemental Biologics License Application (sBLA) for IMFINZI® (durvalumab) in the treatment of …
AstraZeneca’s IMFINZI® Granted Priority Review for Early-Stage Gastric Cancer Treatment Read More WILMINGTON, DE — Incyte (Nasdaq: INCY) will present new clinical data from its oncology pipeline at the upcoming European Society of Medical Oncology (ESMO) Congress, set for October 17–21 in Berlin. …
Incyte to Spotlight Next-Generation Cancer Therapies at ESMO 2025 Read More